Suppr超能文献

利用外周血细胞计数改善国际预后指数评分:一项涉及 520 例弥漫性大 B 细胞淋巴瘤患者的大型多中心研究结果。

Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma.

机构信息

Fondazione Italiana Linfomi, Onlus, Modena, Italy.

Dipartimento di Scienze Mediche e Chirurgiche Materno-Infantili e dell'Adulto, Università di Modena e Reggio Emilia, Modena, Italy.

出版信息

Hematol Oncol. 2020 Oct;38(4):439-445. doi: 10.1002/hon.2757. Epub 2020 Jun 17.

Abstract

The main purpose of this study was to assess whether it is possible to improve the prognostic impact of international prognostic index (IPI) score by combining it with peripheral blood counts. Thus, we evaluated the prognostic power of lymphocyte, neutrophil, and monocyte counts in 520 patients with diffuse large B cell lymphoma treated with R-CHOP, confirming that these parameters have a strong impact on overall survival (OS). Using revised IPI (R-IPI), 44% of patients were categorized as poor-risk and showed an OS at 5 years of 46%. As OS at 5 years of the 520 patients is 67%, it is clearly evident that R-IPI tends to overestimate the proportion of patients with poor prognosis. Accordingly, in an attempt to improve the discriminating power of R-IPI, we evaluated and compared three different scores by combining the neutrophil lymphocyte ratio (NLR) and absolute monocyte count (AMC) with the following values: (a) IPI score 3-5, (b) age > 60 years and performance status, (c) age  ≥ 65 years and LDH > ULN. The three indexes studied, had a similar 5 years OS for the high-risk group (46%-52%), but the proportion of patients classified as poor-risk were 37%, 20%, and 32%, respectively, which are lower than 44% identified with R-IPI. Thus, while R-IPI overestimates the number of high-risk patients, after applying our models, it is possible to recognize patients who are truly at high-risk. Of the three scores, the most accurate appears to be that based on NLR, AMC, LDH > ULN and age ≥ 65 years, which identifies 32% of high-risk patients, correlating well with what is seen in clinical practice.

摘要

本研究的主要目的是评估是否可以通过结合外周血计数来改善国际预后指数(IPI)评分的预后影响。因此,我们评估了淋巴细胞、中性粒细胞和单核细胞计数在 520 例接受 R-CHOP 治疗的弥漫性大 B 细胞淋巴瘤患者中的预后能力,证实这些参数对总生存(OS)有很强的影响。使用修订的 IPI(R-IPI),44%的患者被归类为不良风险,5 年 OS 为 46%。由于 520 例患者的 5 年 OS 为 67%,显然 R-IPI 倾向于高估预后不良患者的比例。因此,为了提高 R-IPI 的判别能力,我们评估并比较了三种不同的评分,方法是将中性粒细胞与淋巴细胞比值(NLR)和绝对单核细胞计数(AMC)与以下值相结合:(a)IPI 评分 3-5,(b)年龄>60 岁和表现状态,(c)年龄≥65 岁和乳酸脱氢酶(LDH)>正常值上限(ULN)。研究的三个指标对高危组的 5 年 OS 相似(46%-52%),但分类为不良风险的患者比例分别为 37%、20%和 32%,低于 R-IPI 确定的 44%。因此,虽然 R-IPI 高估了高危患者的数量,但在应用我们的模型后,可以识别出真正处于高危状态的患者。在这三个评分中,似乎最准确的是基于 NLR、AMC、LDH>ULN 和年龄≥65 岁的评分,该评分识别出 32%的高危患者,与临床实践中的情况相符。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d21/7687198/8f6dce52049a/HON-38-439-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验